Bright Minds Biosciences Inc.
DRUG · Nasdaq · United States
Share price · DRUG
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when DRUG's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026-17.7%
- 2 Nov 2026-52.3%
- 21 Oct 2026-8.6%
Nothing announced by DRUG that day or the session before.
- 7 Oct 2026+7.8%
Nothing announced by DRUG that day or the session before.
- 24 Sep 2026-7.6%
Nothing announced by DRUG that day or the session before.
- 9 Jul 2026+11.9%
Nothing announced by DRUG that day or the session before.
- 8 Jul 2026+8.1%
Nothing announced by DRUG that day or the session before.
- 10 Jun 2026-9.2%
Nothing announced by DRUG that day or the session before.
- 1 Jun 2026-8.0%
Nothing announced by DRUG that day or the session before.
- 20 May 2026+11.1%
Share of unusual movement by asset
For each asset, the share of DRUG's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Serotonin 5-HT2C receptor (biased agonist)Small molecule | EpilepsyDevelopmental and Epileptic Encephalopathies Absence Seizures |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $0.9M | $4.2M | $0.5M-$1.4M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($9.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-04-28 | Cormorant Asset Management, LP; Chen Bihua; Cormorant Global Healthcare Master Fund, LP · Former 10% Owner; Former 10% Owner; Former 10% Owner | Open-market sale | 109,331 | $89.50 | $9.8M | Form 4 |
| 2024-11-04 | Cormorant Asset Management, LP; Chen Bihua · 10% owner; 10% owner | Open-market purchase | 184,331 | $21.70 | $4.0M | Form 4 |
| 2024-10-16 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% owner | Open-market purchase | 39,743 | $23.21 | $923K | Form 4 |
| 2024-10-16 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% owner | Open-market purchase | 7,150 | $24.03 | $172K | Form 4 |
| 2024-10-16 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% owner | Open-market purchase | 3,107 | $25.22 | $78K | Form 4 |
| 2024-10-15 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% owner | Open-market purchase | 238,097 | $4.53 | $1.1M | Form 4 |
| 2024-10-15 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% owner | Open-market purchase | 63,173 | $5.92 | $374K | Form 4 |
| 2024-10-15 | Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Chen Bihua · 10% owner; 10% owner; 10% owner | Open-market purchase | 33,343 | $6.42 | $214K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 93 reporting institutions held 9.2M shares ($669.7M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 1,284,324 | $93.5M |
| 2 | Cormorant Asset Management, LP | 1,059,331 | $77.3M |
| 3 | BlackRock, Inc. | 621,933 | $45.4M |
| 4 | Vivo Capital, LLC | 557,172 | $40.7M |
| 5 | BRAIDWELL LP | 539,708 | $39.4M |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 495,743 | $36.2M |
| 7 | Vestal Point Capital, LP | 492,319 | $35.9M |
| 8 | Driehaus Capital Management LLC | 432,515 | $31.6M |
| 9 | PERCEPTIVE ADVISORS LLC | 377,544 | $27.5M |
| 10 | Balyasny Asset Management L.P. | 297,158 | $21.7M |
| 11 | DEERFIELD MANAGEMENT COMPANY, L.P. | 283,000 | $20.7M |
| 12 | RA CAPITAL MANAGEMENT, L.P. | 265,000 | $19.3M |
| 13 | GREAT POINT PARTNERS LLC | 220,000 | $16.1M |
| 14 | MPM BIOIMPACT LLC | 212,175 | $15.5M |
| 15 | Ikarian Capital, LLC | 166,647 | $12.2M |